45 related articles for article (PubMed ID: 21668581)
1. Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.
Jin X; Liu X; Zhou Z; Ding Y; Wu Y; Qiu J; Shen C
Cancer Immunol Immunother; 2022 Jul; 71(7):1569-1582. PubMed ID: 34724090
[TBL] [Abstract][Full Text] [Related]
2. GPC3 Promotes Lung Squamous Cell Carcinoma Progression and HLA-A2-Restricted GPC3 Antigenic Peptide-Modified Dendritic Cell-Induced Cytotoxic T Lymphocytes to Kill Lung Squamous Cell Carcinoma Cells.
Ning J; Ding J; Wang S; Jiang Y; Wang D; Jiang S
J Immunol Res; 2023; 2023():5532617. PubMed ID: 37965271
[TBL] [Abstract][Full Text] [Related]
3. Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.
Yamada A; Kawano K; Harashima N; Niiya F; Nagai K; Kobayashi T; Mine T; Ushijima K; Nishida T; Itoh K
Cancer Immunol Immunother; 1999; 48(2-3):147-52. PubMed ID: 10414469
[TBL] [Abstract][Full Text] [Related]
4. Administration of a glypican-3 peptide increases the infiltration and cytotoxicity of CD8
Zhao J; Qin L; He G; Xie T; Hu G; Wang F; Zhong H; Zhu J; Xu Y
Cancer Med; 2023 Dec; 12(23):21293-21307. PubMed ID: 37986544
[TBL] [Abstract][Full Text] [Related]
5. A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy.
Peper JK; Stevanović S
Cancer Immunol Immunother; 2015 Oct; 64(10):1295-303. PubMed ID: 25822767
[TBL] [Abstract][Full Text] [Related]
6. Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma.
Ukai M; Yokoi A; Yoshida K; Suzuki S; Shibata K; Kikkawa F; Nakatsura T; Kajiyama H
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535558
[TBL] [Abstract][Full Text] [Related]
7. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
[TBL] [Abstract][Full Text] [Related]
8. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.
Suzuki S; Sakata J; Utsumi F; Sekiya R; Kajiyama H; Shibata K; Kikkawa F; Nakatsura T
Oncoimmunology; 2016; 5(11):e1238542. PubMed ID: 27999758
[TBL] [Abstract][Full Text] [Related]
10. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.
Ofuji K; Saito K; Yoshikawa T; Nakatsura T
J Hepatocell Carcinoma; 2014; 1():35-42. PubMed ID: 27508174
[TBL] [Abstract][Full Text] [Related]
11. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.
Kobayashi H; Sugimoto H; Onishi S; Nakano K
Oncol Lett; 2015 Aug; 10(2):612-618. PubMed ID: 26622542
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.
Yamashita Y
Jpn J Clin Oncol; 2015 May; 45(5):405-7. PubMed ID: 25583423
[TBL] [Abstract][Full Text] [Related]
13. GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth.
Luo C; Shibata K; Suzuki S; Kajiyama H; Senga T; Koya Y; Daimon M; Yamashita M; Kikkawa F
Oncol Rep; 2014 Sep; 32(3):913-21. PubMed ID: 24992906
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
[TBL] [Abstract][Full Text] [Related]
15. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
Suzuki S; Shibata K; Kikkawa F; Nakatsura T
Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
[TBL] [Abstract][Full Text] [Related]
16. Peptide vaccines for hepatocellular carcinoma.
Nobuoka D; Yoshikawa T; Sawada Y; Fujiwara T; Nakatsura T
Hum Vaccin Immunother; 2013 Jan; 9(1):210-2. PubMed ID: 23442593
[TBL] [Abstract][Full Text] [Related]
17. A glypican-3-derived peptide vaccine against hepatocellular carcinoma.
Sawada Y; Sakai M; Yoshikawa T; Ofuji K; Nakatsura T
Oncoimmunology; 2012 Nov; 1(8):1448-1450. PubMed ID: 23243625
[TBL] [Abstract][Full Text] [Related]
18. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y; Gao W; Man YG; Nagata S; Ho M
MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
